EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

A Survival Analysis of Patients with Recurrent Epithelial Ovarian Cancer Based on Relapse Type: A Multi-Institutional Retrospective Study in Armenia

Lilit Harutyunyan iD, Evelina Manvelyan iD, Nune Karapetyan, Samvel Bardakhchyan, Aram Jilavyan, Gevorg Tamamyan, Armen Avagyan, Liana Safaryan, Davit Zohrabyan, Narine Movsisyan, Anna Avinyan, Arevik Galoyan und 8 weitere

Current Oncology · 2024

DOI: 10.3390/curroncol31030100 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Current Oncology, 2024. Verfasst von Lilit Harutyunyan und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Oncology, Yerevan State Medical University after M. Heratsi, 2 Koryun St., Yerevan 0025, Armenia. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Ovarian Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Annually, approximately 200 new ovarian cancer cases are diagnosed in Armenia, which is considered an upper-middle-income country. This study aimed to summarize the survival outcomes of patients with relapsed ovarian cancer in Armenia based on the type of recurrence, risk factors, and choice of systemic treatment.

Methods

This retrospective case-control study included 228 patients with relapsed ovarian cancer from three different institutions.

Results

The median age of the patients was 55. The median follow-up times from relapse and primary diagnosis were 21 and 48 months, respectively. The incidence of platinum-sensitive relapse was 81.6% (186), while platinum-resistant relapse was observed in only 18.4% (42) of patients. The median post-progression survival of the platinum-sensitive group compared to the platinum-resistant group was 54 vs. 25 months (p < 0.001), respectively, while the median survival after relapse was 25 vs. 13 months, respectively; three- and five-year post-progression survival rates in these groups were 31.2% vs. 23.8%, and 15.1% vs. 9.5%, respectively (p = 0.113).

Conclusions

Overall, despite new therapeutic approaches, ovarian cancer continues to be one of the deadly malignant diseases affecting women, especially in developing countries with a lack of resources, where chemotherapy remains the primary available systemic treatment for the majority of patients. Low survival rates demonstrate the urgent need for more research focused on this group of patients with poor outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm Recurrence, LocalOvarian NeoplasmsHumansFemaleCarcinoma, Ovarian EpithelialRetrospective StudiesCase-Control StudiesArmeniaSurvival AnalysisRecurrence

Stichwörter der Autor:innen

chemotherapyplatinum-refractory relapseplatinum-resistant relapseplatinum-sensitive relapserecurrent ovarian cancertargeted therapy

Autor:innen und Institutionen

  • Department of General Oncology, Yerevan State Medical University after M. Heratsi, 2 Koryun St., Yerevan 0025, Armenia.
  • Oncology Clinic, Mikaelyan Institute of Surgery, Ezras Hasratian 9, Yerevan 0052, Armenia.
  • Department of Reproductive Biology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
  • Clinic of Adults' Oncology and Chemotherapy at Yeolyan Hematology and Oncology Center, 7 Nersisyan St., Yerevan 0014, Armenia.
  • Immune Oncology Research Institute, 7 Nersisyan St., Yerevan 0014, Armenia.
  • Yeolyan Hematology and Oncology Center, 7 Nersisyan St., Yerevan 0014, Armenia.

ORCID-Profile: Lilit Harutyunyan, Evelina Manvelyan

Zitieren

APA

Harutyunyan, L., Manvelyan, E., Karapetyan, N., Bardakhchyan, S., Jilavyan, A., Tamamyan, G., Avagyan, A., Safaryan, L., Zohrabyan, D., Movsisyan, N., Avinyan, A., Galoyan, A., Sargsyan, M., Harutyunyan, M., Nersoyan, H., Stepanyan, A., Galstyan, A., Danielyan, S., Muradyan, A., & Jilavyan, G. (2024). A Survival Analysis of Patients with Recurrent Epithelial Ovarian Cancer Based on Relapse Type: A Multi-Institutional Retrospective Study in Armenia. Current Oncology. https://doi.org/10.3390/curroncol31030100

Vancouver

Harutyunyan L, Manvelyan E, Karapetyan N, Bardakhchyan S, Jilavyan A, Tamamyan G, et al. A Survival Analysis of Patients with Recurrent Epithelial Ovarian Cancer Based on Relapse Type: A Multi-Institutional Retrospective Study in Armenia. Current Oncology. 2024. doi:10.3390/curroncol31030100

BibTeX
@article{Harutyunyan2024,
  author = {Harutyunyan, Lilit and Manvelyan, Evelina and Karapetyan, Nune and Bardakhchyan, Samvel and Jilavyan, Aram and Tamamyan, Gevorg and Avagyan, Armen and Safaryan, Liana and Zohrabyan, Davit and Movsisyan, Narine and Avinyan, Anna and Galoyan, Arevik and Sargsyan, Mariam and Harutyunyan, Martin and Nersoyan, Hasmik and Stepanyan, Arevik and Galstyan, Armenuhi and Danielyan, Samvel and Muradyan, Armen and Jilavyan, Gagik},
  title = {A Survival Analysis of Patients with Recurrent Epithelial Ovarian Cancer Based on Relapse Type: A Multi-Institutional Retrospective Study in Armenia},
  journal = {Current Oncology},
  year = {2024},
  doi = {10.3390/curroncol31030100}
}
Kostenlos starten →